Study on Frontline Therapy for Advanced Classical Hodgkin Lymphoma

Sponsor: Takeda

Sponsor score: 60
Inactive

ClinicalTrials ID:NCT01712490

Provider View

This clinical trial is comparing two treatment options for people with advanced classical Hodgkin Lymphoma to see which one is more effective in delaying the progression of the disease.

Patient Parameters

Program Overview

This study is testing two different treatment combinations for people with advanced classical Hodgkin Lymphoma (HL). The goal is to find out which treatment is better at stopping the disease from getting worse. Participants will receive either a combination of brentuximab vedotin with AVD (doxorubicin, vinblastine, and dacarbazine) or the standard ABVD treatment (doxorubicin, bleomycin, vinblastine, and dacarbazine).

Eligibility Criteria

Inclusion Criteria

  • Have not received any treatment for Hodgkin Lymphoma and have Stage III or IV disease.
  • Have a confirmed diagnosis of classical Hodgkin Lymphoma based on current medical guidelines.
  • Be in relatively good health with an ECOG performance status of 2 or less, meaning you are able to carry out all self-care but unable to carry out any work activities.
  • Have measurable disease that can be assessed using imaging techniques.

Exclusion Criteria

  • Have a type of Hodgkin Lymphoma called nodular lymphocyte predominant.
  • Have disease affecting the brain or spinal cord, including symptoms of a condition called progressive multifocal leukoencephalopathy (PML).
  • Have nerve damage affecting sensation or movement.
  • Have received chemotherapy, radiation, or immunotherapy within 12 weeks before starting the study treatment.
  • Have tested positive for HIV.
  • Have active hepatitis B or C infections.

Please note that there are additional exclusion criteria. The study center will determine if you meet all of the criteria.

Get This Program In Your Inbox

Receive detailed information about this treatment opportunity to review with your healthcare provider.